Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data
Open Access
- 6 April 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (4) , e0271354
Abstract
Tumors rich in stroma are associated with advanced stage and poor prognosis in colorectal adenocarcinoma (CRC). Abundance of stromal cells also has implications for genomic analysis of patient tumors as it may prevent detection of somatic mutations. As part of our efforts to interrogate stroma-cancer cell interactions and to identify actionable therapeutic targets in metastatic CRC, we aimed to determine the proportion of stroma embedded in hepatic CRC metastases by performing computational tumor purity analysis based on whole exome sequencing data (WES). Unlike previous studies focusing on histopathologically prescreened samples, we used an unbiased in-house collection of tumor specimens. WES from CRC liver metastasis samples were utilized to evaluate stromal content and to assess the performance of three in silico tumor purity tools, ABSOLUTE, Sequenza and PureCN. Matching tumor derived organoids were analyzed as a high purity control as they are enriched in cancer cells. Computational purity estimates were compared to those from a histopathological assessment conducted by a board-certified pathologist. According to all computational methods, metastatic specimens had a median tumor purity of 30% whereas the organoids were enriched for cancer cells with a median purity estimate of 94%. In line with this, variant allele frequencies (VAFs) of oncogenes and tumor suppressor genes were undetectable or low in most patient tumors, but higher in matching organoid cultures. Positive correlation was observed between VAFs and in silico tumor purity estimates. Sequenza and PureCN produced concordant results whereas ABSOLUTE yielded lower purity estimates for all samples. Our data shows that unbiased sample selection combined with molecular, computational, and histopathological tumor purity assessment is critical to determine the level of stroma embedded in metastatic colorectal adenocarcinoma.Keywords
Funding Information
- Cancer Research Coordinating Committee (C21CR2154)
- Edmund Wattis Littlefield Foundation (Private gift)
This publication has 22 references indexed in Scilit:
- Sequenza: allele-specific copy number and mutation profiles from tumor sequencing dataAnnals of Oncology, 2014
- An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samplesBriefings in Bioinformatics, 2014
- Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17AJournal of Experimental Medicine, 2013
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Absolute quantification of somatic DNA alterations in human cancerNature Biotechnology, 2012
- Accessories to the Crime: Functions of Cells Recruited to the Tumor MicroenvironmentCancer Cell, 2012
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010
- The proportion of tumour cells is an independent predictor for survival in colorectal cancer patientsBritish Journal of Cancer, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009